drugset

drugset / Trial / NCT00373776

Miltefosine for Mucosal Leishmaniasis

NCT00373776 ↗

Phase 1/2 Completed 75 enrolled AB Foundation

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This trial will study miltefosine as a treatment for mucosal leishmaniasis.

Timeline

Start: 2004-04
Primary completion: —
Completion: 2006-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Miltefosine	Small molecule	2.5 mg/kg	—

Indications